Advertisement

Adverse Effects of Cancer Treatment of Hearing

  • Wendy Landier
  • Thomas E. Merchant
Part of the Pediatric Oncology book series (PEDIATRICO)

Keywords

Hearing Loss Hair Cell Cochlear Implant Sensorineural Hearing Loss Loop Diuretic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bates DE (2003) Aminoglycoside ototoxicity. Drugs Today (Barc) 39:277–285CrossRefGoogle Scholar
  2. 2.
    Bates DE, Beaumont SJ, Baylis BW (2002) Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother 36:446–451CrossRefPubMedGoogle Scholar
  3. 3.
    Brock PR, Bellman SC, Yeomans EC et al. (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19:295–300PubMedGoogle Scholar
  4. 4.
    Brookhouser PE (2000) Diseases of the cochlea and labrynth. In:Wetmore RF, Muntz HR, McGill TJ (eds) Pediatric otolaryngology: principles and practice pathways. Thieme, New York, pp 327–354Google Scholar
  5. 5.
    Brookhouser PE, Beauchaine KL, Osberger MJ (1999) Management of the child with sensorineural hearing loss. Medical, surgical, hearing aids, cochlear implants. Pediatr Clin North Am 46:121–141PubMedGoogle Scholar
  6. 6.
    Campbell KC, Durrant J (1993) Audiologic monitoring for ototoxicity. Otolaryngol Clin North Am 26:903–914PubMedGoogle Scholar
  7. 7.
    Cherow E, Dickman DM, Epstein S (1999) Organization resources for families of children with deafness or hearing loss. Pediatr Clin North Am 46:153–162CrossRefPubMedGoogle Scholar
  8. 8.
    Chao WY, Leung HW (1995) Effects of irradiation on the rat middle ear mucosa. A scanning electron microscopic study. Eur Arch Otorhinolaryngol 252:244–248CrossRefPubMedGoogle Scholar
  9. 9.
    Doolittle ND, Muldoon LL, Brummett RE et al. (2001) Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493–500PubMedGoogle Scholar
  10. 10.
    Fee WE Jr (1980) Aminoglycoside ototoxicity in the human. Laryngoscope 90[Suppl 24]:1–19Google Scholar
  11. 11.
    Francis HW, Niparko JK (2003) Cochlear implantation update. Pediatr Clin North Am 50:341–346CrossRefPubMedGoogle Scholar
  12. 12.
    Gamble JE, Peterson EA, Chandler JR (1968) Radiation effects on the inner ear. Arch Otolaryng 88:156–161PubMedGoogle Scholar
  13. 13.
    Gratton MA, Salvi RJ, Kamen BA et al. (1990) Interaction of cisplatin and noise on the peripheral auditory system. Hear Res 50:211–223CrossRefPubMedGoogle Scholar
  14. 14.
    Grau C, Moller K, Overgaard M et al. (1991) Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21:723–728PubMedGoogle Scholar
  15. 15.
    Hale GA, Marina NM, Jones-Wallace D et al. (1999) Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol 21:115–122CrossRefPubMedGoogle Scholar
  16. 16.
    Hall JW (2000) Handbook of otoacoustic emissions. Singular, San DiegoGoogle Scholar
  17. 17.
    Huang E, Teh BS, Strother DR et al. (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52:599–605CrossRefPubMedGoogle Scholar
  18. 18.
    Ilveskoski I, Saarinen UM, Wiklund T et al. (1996) Ototoxicity in children with malignant brain tumors treated with the “8 in 1” chemotherapy protocol. Med Pediatr Oncol 27:26–31CrossRefPubMedGoogle Scholar
  19. 19.
    Kapoor G, Warrier RP, Shah SJ et al. (1996) Cisplatin and cranial irradiation related hearing loss in children. Proc ASCO 15:1436Google Scholar
  20. 20.
    Kemp G, Rose P, Lurain J et al. (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101–2112PubMedGoogle Scholar
  21. 21.
    Landier W, Larson-Tuttle C (2004) Monitoring and management of ototoxicity. In: Altman AJ (ed) Supportive care of children with cancer: current therapy and guidelines from the children's oncology group, 3rd edn. Johns Hopkins University Press, Baltimore, pp 130–138Google Scholar
  22. 22.
    Lerner SA, Schmitt BA, Seligsohn R et al. (1986) Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 80:98–104CrossRefGoogle Scholar
  23. 23.
    Low WK, Fong KW (1998) Long-term post-irradiation middle ear effusion in nasopharyngeal carcinoma. Auris Nasus Larynx 25:319–321CrossRefPubMedGoogle Scholar
  24. 24.
    Macdonald MR, Harrison RV, Wake M et al. (1994) Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol 23:151–159PubMedGoogle Scholar
  25. 25.
    Mann WJ, Maurer J, Marangos N (2002) Neural conservation in skull base surgery. Otolaryngol Clin North Am 35:411–424, ixCrossRefPubMedGoogle Scholar
  26. 26.
    Marina N, Malogolowkin M, London WB et al. (2003) Amifostine does not protect against the Ototoxicity associated with high-dose cisplatin, etoposide and bleomycin (HD-PEB) in pediatric germ cell tumors (PGCT): a PGCT Intergroup Study. Proceedings of the American Society of Clinical Oncology, 31 May–3 June 2003, Chicago IL, p 798Google Scholar
  27. 27.
    Matz GJ (1993) Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am 26:705–712PubMedGoogle Scholar
  28. 28.
    Merchant TE, Gould CJ, Xiong X et al. (2002) Early neurootologic effects of three-dimensional irradiation in children with primary brain tumors. 44th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), New Orleans, LA, 6–10 Oct 2002. Int J Radiat Oncology Biol Phys 54:201CrossRefGoogle Scholar
  29. 29.
    Meyer WH, Ayers D, McHaney VA et al. (1993) Ifosfamide and exacerbation of cisplatin-induced hearing loss. Lancet 341:754–755CrossRefGoogle Scholar
  30. 30.
    Neuwelt EA, Brummett RE, Doolittle ND (1998) First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 286:77–84PubMedGoogle Scholar
  31. 31.
    Parsons SK, Neault MW, Lehmann LE et al. (1998) Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:669–674CrossRefPubMedGoogle Scholar
  32. 32.
    Peters U, Preisler-Adams S, Hebeisen A et al. (2000) Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 11:639–643PubMedGoogle Scholar
  33. 33.
    Riggs LC, Brummett RE, Guitjens SK et al. (1996) Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope 106:401–406CrossRefPubMedGoogle Scholar
  34. 34.
    Roland JT, Cohen NL (1998) Vestibular and auditory ototoxicity. In: Cummings CW, Fredrickson JM, Harker LA, Krause CJ, Schuller DE, Richardson MA (eds) Otolaryngology head and neck surgery, 3rd edn. Mosby, St Louis, pp 3186–3197Google Scholar
  35. 35.
    Rybak LP (1993) Ototoxicity of loop diuretics. Otolaryngol Clin North Am 26:829–844PubMedGoogle Scholar
  36. 36.
    Schell MJ, McHaney VA, Green AA et al. (1989) Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7:754–760PubMedGoogle Scholar
  37. 37.
    Schweitzer VG (1993) Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am 26:759–789PubMedGoogle Scholar
  38. 38.
    Senan S, Rampling R, Graham MA et al. (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3:31–38PubMedGoogle Scholar
  39. 39.
    Simon T, Hero B, Dupuis W et al. (2002) The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr 214:149–152CrossRefPubMedGoogle Scholar
  40. 40.
    Sininger YS, Doyle KJ, Moore JK (1999) The case for early identification of hearing loss in children: auditory system development, experimental auditory deprivation, and development of speech perception and hearing. Pediatr Clin North Am 46:1–14CrossRefPubMedGoogle Scholar
  41. 41.
    Smith CR, Lipsky JJ, Laskin OL et al. (1980) Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 302:1106–1109PubMedGoogle Scholar
  42. 42.
    Stach BA (1998) Clinical audiology: an introduction. San Diego, pp 208–209; 292–312Google Scholar
  43. 43.
    Stringer SP, Meyerhoff WL, Wright CG (1991) Ototoxicity. In: Paparella MM, Shumrick DA (eds) Otolaryngology, 3rd edn. Saunders, Philadelphia, pp.1653–1669Google Scholar
  44. 44.
    Takeno S, Harrison RV, Ibrahim D et al. (1994) Cochlear function after selective inner hair cell degeneration induced by carboplatin. Hear Res 75:93–102CrossRefPubMedGoogle Scholar
  45. 45.
    Weatherly RA, Owens JJ, Catlin FI et al. (1991) Cis-platinum ototoxicity in children. Laryngoscope 101:917–924PubMedGoogle Scholar
  46. 46.
    Young YH, Lu YC (2001) Mechanism of hearing loss in irradiated ears: a long-term longitudinal study. Ann Otol Rhinol Laryngol 110:904–906PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Wendy Landier
  • Thomas E. Merchant

There are no affiliations available

Personalised recommendations